Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
Part of paid clinical trials in St Louis, Missouri.
- Sponsor
- Washington University School of Medicine
- Study ID
- NCT01999270
- Phase
- PHASE1
- Status
- Completed
Conditions
- Astrocytoma, Oligoastrocytoma, Mixed
- Ganglioglioma
- Ganglioneuroma
- Glioblastoma Multiforme Glioma
- Glioma
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 21 Years
- Healthy Volunteers
- Not accepted
Interventions
- Irinotecan — DRUGIrinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29) Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
- Bevacizumab — DRUGBevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.
- FDOPA-PET/MRI imaging — DEVICEFDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
Study Details
To determine if FDOPA-PET/MRI imaging can predict response to treatment of bevacizumab.
Key Dates
- Start date
- Apr 30, 2013
- Status verified
- Oct 2016
- Primary completion
- May 31, 2016
- Completion
- May 31, 2016
Study Design
- Enrollment
- 6 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Irinotecan, Bevacizumab and FDOPA-PET/MRI imagingIrinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
Primary Outcome Measure
FDOPA-PET/MRI imaging [ Time Frame: 1 year ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | - |
Find similar trials in St Louis, MO
By condition
By specialty
By research site
Related Studies
- Project: Every Child for Younger Patients With CancerRecruiting · Children's Oncology Group · Birmingham, Alabama
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)PHASE3 · Recruiting · Nuvation Bio Inc. · Birmingham, Alabama
- ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)PHASE3 · Recruiting · Jazz Pharmaceuticals · Phoenix, Arizona
- Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIPHASE2 · Recruiting · Black Diamond Therapeutics, Inc. · Springdale, Arkansas